ERYTECH to Participate in the Citi 16th Annual BioPharma Conference

Rhea-AI Summary

ERYTECH Pharma announced its participation in the Citi 16th Annual BioPharma Conference from September 8-10, 2021. The company, recognized for its innovative therapies encapsulating drug substances in red blood cells, will host virtual one-on-one meetings with investors. Key executives, including CEO Gil Beyen and CFO Eric Soyer, will be present. ERYTECH is focused on its lead product candidate, eryaspase, which targets cancer metabolism and is currently in Phase 3 for second-line pancreatic cancer.

ERYTECH to Participate
in the Citi 16^th Annual BioPharma Conference

---

Cambridge, MA (U.S.) and Lyon (France), August 30, 2021 – ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced its participation in the Citi 16^th Annual BioPharma Conference and invites investors to join virtually via one-on-one meetings.

Citi’s 16^th Annual BioPharma Conference– September 8 -10, 2021

Gil Beyen, Chief Executive Officer, Eric Soyer Chief Financial Officer and Dr. Iman El-Hariry, Chief Medical Officer, will participate in one-on-one meetings on Wednesday September 8^th through Friday September 10^th.

If you are interested in arranging a one-on-one meeting, please contact your Citigroup representative. For more information about the Citi 16th Annual BioPharma Conference, please refer to the Citi conference website http://citiconferences.com/other.php.

About ERYTECH and eryaspase

ERYTECH is a clinical-stage biopharmaceutical company developing innovative red blood cell-based therapeutics for severe forms of cancer and orphan diseases. Leveraging its proprietary ERYCAPS® platform, which uses a novel technology to encapsulate drug substances inside red blood cells, ERYTECH is developing a pipeline of product candidates for patients with high unmet medical needs. ERYTECH’s primary focus is on the development of product candidates that target the altered metabolism of cancer cells by depriving them of amino acids necessary for their growth and survival.

The Company’s lead product candidate, eryaspase, which consists of L-asparaginase encapsulated inside donor-derived red blood cells, targets the cancer cells’ altered asparagine and glutamine metabolism. Eryaspase is in a Phase 3 clinical development for the treatment of second-line pancreatic cancer, which is fully enrolled and expected to read out final results in Q4 2021, and in an ongoing Phase 2 for the treatment of triple-negative breast cancer. An investigator sponsored Phase 2 trial (IST) in acute lymphoblastic leukemia recently reported positive results, and a Phase 1 IST in 1L advanced pancreatic cancer is ongoing.

Eryaspase received Fast Track designation from the U.S. Food and Drug Administration (FDA) for the treatment of advanced pancreatic cancer and treatment of acute lymphoblastic leukemia (ALL) patients who have developed hypersensitivity reactions to E. coli-derived pegylated asparaginase (PEG-ASNase). The FDA and the European Medicines Agency have granted eryaspase orphan drug status for the treatment of pancreatic cancer and ALL.

ERYTECH produces its product candidates for treatment of patients in Europe at its GMP-approved manufacturing site in Lyon, France, and for patients in the United States at its GMP manufacturing site in Princeton, New Jersey, USA. Eryaspase is not an approved medicine.

ERYTECH is listed on the Nasdaq Global Select Market in the United States (ticker: ERYP) and on the Euronext regulated market in Paris (ISIN code: FR0011471135, ticker: ERYP). ERYTECH is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes.        
For more information, please visit www.erytech.com        

CONTACTS

ERYTECH                      Eric Soyer CFO & COO	LifeSci Advisors, LLC Corey Davis, Ph.D. Investor relations	NewCap Mathilde Bohin / Louis-Victor Delouvrier Investor relations Nicolas Merigeau Media relations
+33 4 78 74 44 38 investors@erytech.com	+1 (212) 915 2577 cdavis@lifesciadvisors.com	+33 1 44 71 94 94 erytech@newcap.eu

Attachment

• 300821_ERYTECH_PR_Citi 16th Annual BioPharma Conference_EN

FAQ

When will ERYTECH participate in the Citi 16th Annual BioPharma Conference?

ERYTECH will participate in the Citi 16th Annual BioPharma Conference from September 8-10, 2021.

What is the focus of ERYTECH's lead product candidate, eryaspase?

Eryaspase targets altered metabolism in cancer cells, specifically depriving them of amino acids necessary for growth.

What clinical trials is ERYTECH currently conducting?

ERYTECH is conducting a Phase 3 trial for eryaspase in second-line pancreatic cancer and a Phase 2 trial for triple-negative breast cancer.

What important designation has eryaspase received from the FDA?

Eryaspase has received Fast Track designation from the FDA for treating advanced pancreatic cancer and acute lymphoblastic leukemia.

Where is ERYTECH headquartered?

ERYTECH is headquartered in Cambridge, MA, USA, and Lyon, France.